DNA based therapy with diphtheria toxin-A BC-819: A phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer

noticia |

Gofrit O.N., Benjamin S., Halachmi S., Leibovitch I., Dotan Z., Lamm D.L., Ehrlich N., Yutkin V., Ben-Am M., Hochberg A.

Journal of Urology 2014 191:6 (1697-1702)

Materials and Methods: A total of 47 patients with recurrent, multiple nonmuscle invasive bladder tumors in whom prior intravesical therapy had failed underwent transurethral resection of all except 1 marker tumor. Patients expressing H19 received a 6-week induction course of intravesical BC-819. Patients who achieved a complete response (absent new tumors at 3 months) were given 3 maintenance courses of 3-weekly instillations every 3 months. Purpose: H19 is a paternally imprinted oncofetal gene expressed in various embryonic tissues and in 85% of bladder tumors but suppressed in the adult healthy bladder…(ver más)

Valora esta noticia

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...